Business
Equillium Announces Poster Presentation at the Annual Meeting of the European Society for Blood and Marrow Transplantation
Itolizumab in combination with systemic corticosteroids was associated with high rates of overall clinical response Response at Day 29 was associated with
About this update from Equillium, Inc.
[{"type":"text","content":"\nItolizumab in combination with systemic corticosteroids was associated with high rates of overall clinical response\n\n\nResponse at Day 29 was associated with improved progression-free survival through 1 year\n\n\nItolizumab is being evaluated in pivotal Phase 3 EQUATOR study in first-line acute graft-versus-host disease\n\n\n LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that an ePoster presentation highlighting data from the EQUATE study in acute graft-versus-host disease (aGVHD) was given yesterday at the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation.\n\n\nThe presentation, given by Dr. Corey Cutler, associate professor of medicine, Dana Farber Cancer Institute, Harvard Medical School, highlights positive final study results, including long-term follow-up data for up to one year, from EQUATE (NCT03763318), a Phase 1b study of itolizumab in combination with corticosteroids (CS) to treat subjects with newly diagnosed severe aGVHD. The data demonstrate promising outcomes in subjects with severe aGVHD. Equillium has since initiated EQUATOR (NCT05263999), a pivotal Phase 3 study of itolizumab as a potential initial therapy for aGVHD in combination with CS.\n\n\n“The full data set from the EQUATE study suggests that itolizumab has potential clinical value for the treatment of aGVHD,” said Dr. Cutler. “There are no drugs approved in the first-line setting of this potentially lethal condition, so I am encouraged to see rapid and durable responses demonstrating high progression-free survival through one year, as well as responders to itolizumab treatment having a clinically meaningful reduction in the use of corticosteroids of ninety-nine percent at six months.”\n\n\nTitle: Final Safety and Efficacy Results from EQUATE, an Open-Label Study Evaluating Itolizumab, a Novel Targeted anti-CD6 Therapy, in Newly Diagnosed Acute Graft-Versus-Host Disease\nPresenting Author: Dr. Corey Cutler\nPoster Number: P322\n\n\nKey Highlights, Summary and Conclusions from Presentation:\n\n\n\nItolizumab treatment in combination with systemic corticosteroids was associated with rapid...